Notice2021-22918
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 21, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 201 (Thursday, October 21, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 201 (Thursday, October 21, 2021)]
[Notices]
[Pages 58288-58289]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-22918]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#18687d6c7d6a366c6d767f58767170367f776e"><span class="__cf_email__" data-cfemail="473722332235693332292007292e2f69202831">[email protected]</span></a>. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to this invention.
SUPPLEMENTARY INFORMATION: Technology description follows.
Novel VAR2CSA Immunogens and Methods of Use Thereof
Description of Technology
The invention provides immunogen polypeptides comprising fragments
of VAR2CSA protein expressed by P. falciparum as potential second-
generation placental malaria vaccine candidates. VAR2CSA is the leading
antigen target for a placental malaria vaccine, where associated
antibody titers are correlated with protection. Aspects of the
inventive immunogen polypeptides comprise all or portions of the
chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified
by a structural study of VAR2CSA conducted by the inventors, that
possess great sequence conservation among P. falciparum strains when
compared to competing clinical vaccine candidates PRIMVAC and PAMVAC.
Also provided are methods of using the immunogen polypeptides for
vaccination and treatment of disease.
[[Page 58289]]
Oncology Application
The VAR2CSA immunogens bind to oncofetal CSA, a putative
therapeutic target for multiple cancers, including NSCLC, breast,
bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only
expressed solely in the placenta, except in several cancerous tissues,
making it an ideal target for targeted therapeutics such as immunogens
that are cross linked to cytotoxic agents.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Placental malaria vaccine
<bullet> CSA-binding proteins for cancer therapeutics
Competitive Advantages:
<bullet> Strain-transcending immunogens for vaccination
<bullet> Improved immunogen production through expression of key
protein regions
Development Stage:
<bullet> Immunogens successfully tested in a small animal model
Inventors: Dr. Niraj Tolia and Dr. Rui Ma, both of NIAID.
Publications: Ma, R. et al., ``Structural basis for placental
malaria mediated by Plasmodium falciparum VAR2CSA'', Nat Microbiol 6,
380-391, 2021.
Intellectual Property: HHS Reference No. E-021-2021-0-US-01--U.S.
Provisional Application No. 63/115,729, filed November 19, 2020.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#7a0a1f0e1f08540e0f141d3a141312541d150c"><span class="__cf_email__" data-cfemail="fa8a9f8e9f88d48e8f949dba949392d49d958c">[email protected]</span></a>.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483;
<a href="/cdn-cgi/l/email-protection#d1a1b4a5b4a3ffa5a4bfb691bfb8b9ffb6bea7"><span class="__cf_email__" data-cfemail="9cecf9e8f9eeb2e8e9f2fbdcf2f5f4b2fbf3ea">[email protected]</span></a>.
Dated: October 15, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-22918 Filed 10-20-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 21, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.